Brief: Diasorin Receives 510(K) Authorization From U.S. FDA For Liaison Plex Gram-Positive Blood Culture Assay
09/06/2025 09:45
June 9 (Reuters) - DiaSorin SpA DIAS.MI: RECEIVES 510(K) AUTHORIZATION FROM U.S. FDA FOR LIAISON PLEX GRAM-POSITIVE BLOOD CULTURE ASSAY AUTHORIZATION COMPLETES PORTFOLIO OF PANELS FOR DIAGNOSIS OF BLOOD INFECTIONS ON LIAISON PLEX Further company coverage: DIAS.MI (Gdansk Newsroom) ((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))
Recent news on DiaSorin SpA
See all newsKepler sees European Medtech recovery, starts BioMerieux at 'Buy' as top pick
Brief: Diasorin Receives Us' FDA 510(K) Clearance And Clia Waiver For Liaison Nes Group A Streptococcus (Gas) Assay
Deutsche Bank cuts Diasorin to 'sell', sees company targets as stretched
Italy - Factors to watch on June 5
Italy's DiaSorin jumps after Betaville reports possible takeover interest